About Nektar Therapeutics
https://www.nektar.comNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally.
CEO
Howard W. Robin
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-09 | Reverse | 1:15 |
| 2000-08-23 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 45
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
OPPENHEIMERFUNDS, INC.
Shares:17.3M
Value:$624.46M
BLACKROCK INC.
Shares:15.16M
Value:$546.97M
BLACKROCK FUND ADVISORS
Shares:13.84M
Value:$499.62M
Summary
Showing Top 3 of 242
About Nektar Therapeutics
https://www.nektar.comNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $11.79M ▲ | $43.46M ▼ | $-35.52M ▲ | -301.29% ▲ | $-1.87 ▲ | $-29.31M ▲ |
| Q2-2025 | $11.18M ▲ | $47.41M ▼ | $-41.59M ▲ | -372.2% ▲ | $-2.95 ▲ | $-33.79M ▲ |
| Q1-2025 | $10.46M ▼ | $54.99M ▲ | $-50.88M ▼ | -486.44% ▼ | $-3.62 ▼ | $-40.97M ▼ |
| Q4-2024 | $29.18M ▲ | $6.85M ▼ | $7.26M ▲ | 24.89% ▲ | $0.52 ▲ | $17.49M ▲ |
| Q3-2024 | $24.12M | $54.03M | $-37.06M | -153.61% | $-2.66 | $-30.04M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $270.21M ▲ | $301.35M ▲ | $216.26M ▼ | $85.09M ▲ |
| Q2-2025 | $175.9M ▼ | $207.53M ▼ | $231.75M ▼ | $-24.21M ▼ |
| Q1-2025 | $218.63M ▼ | $256.24M ▼ | $242.5M ▼ | $13.74M ▼ |
| Q4-2024 | $255.23M ▲ | $303.85M ▼ | $243.11M ▼ | $60.74M ▲ |
| Q3-2024 | $244.5M | $307.97M | $259.08M | $48.88M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-35.52M ▲ | $-48.76M ▼ | $-94.87M ▼ | $141.68M ▲ | $-1.96M ▼ | $-48.88M ▼ |
| Q2-2025 | $-41.59M ▲ | $-45.74M ▲ | $49.62M ▲ | $211K ▲ | $4.09M ▲ | $-45.77M ▲ |
| Q1-2025 | $-50.88M ▼ | $-49.05M ▼ | $43.69M ▼ | $7K ▼ | $-5.36M ▼ | $-49.05M ▼ |
| Q4-2024 | $7.26M ▲ | $-46.19M ▼ | $60.21M ▲ | $83K ▲ | $14.14M ▲ | $-46.65M ▼ |
| Q3-2024 | $-37.06M | $-43.93M | $46.12M | $13K | $2.14M | $-44.6M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License Collaboration And Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Non Cash Royalty Revenue Related To Sale Of Future Royalties | $30.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Product | $20.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Howard W. Robin
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-09 | Reverse | 1:15 |
| 2000-08-23 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 45
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
OPPENHEIMERFUNDS, INC.
Shares:17.3M
Value:$624.46M
BLACKROCK INC.
Shares:15.16M
Value:$546.97M
BLACKROCK FUND ADVISORS
Shares:13.84M
Value:$499.62M
Summary
Showing Top 3 of 242